Solstice Biologics has named Lou Tartaglia as its president and CEO, as well as a member of its board of directors.

Tartaglia was previously a partner at Third Rock Ventures, and before that was a senior vice president at GeneLogic.

Solstice also said that it has appointed John Borgeson as its CFO. He acted as a financial advisor to Solstice from its inception earlier this year, and previously held a variety of roles at Pfizer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Futurism writes that gene doping could be the next generation of cheating in sports.

May
08
Sponsored by
Dovetail Genomics

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.